Literature DB >> 29374717

Effect of Neoadjuvant Chemoradiotherapy on Lymph Node Micrometastases in Thoracic Esophageal Cancer.

Masayuki Yanagi1,2, Ken Sasaki3, Yasuto Uchikado1, Itaru Omoto1, Takaaki Arigami1, Hiroshi Kurahara1, Yoshikazu Uenosono1, Masahiko Sakoda1, Kosei Maemura1, Shoji Natsugoe1.   

Abstract

AIM: The purpose of this study was to clarify the effect of neoadjuvant chemoradiotherapy (nCRT) on lymph node micrometastasis (LNM) in esophageal squamous cell carcinoma (ESCC). PATIENTS AND METHODS: The therapeutic efficacy of nCRT was analyzed in 41 ESCC patients randomized to the Surgery group (n=21) and the nCRT group (n=20). Lymph node specimens from patients were classified into two categories, micrometastasis (MM) and tumor cell microinvolvement (MI), after immunohistochemical evaluation.
RESULTS: The incidence rates of patients presenting MM with or without MI or MI alone in the Surgery group were significantly higher than those in the nCRT group. The 10-year survival rate of 15 patients with simultaneous histological metastasis (HM) and LNM was significantly lower than that in the 26 patients without LNM. Within the nCRT group, the 10-year survival rates of patients with versus those without HM were not significantly different; however, the 10-year survival rate of the 5 patients with simultaneous HM and LNM was significantly lower than that of the 15 patients without LNM.
CONCLUSION: ESCC patients with LNM may benefit from nCRT, and evaluation of the simultaneous presence of HM and LNM may facilitate accurate prediction of survival in ESCC patients. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Lymph node metastasis; cytokeratin; esophageal cancer; lymph node micrometastasis; neoadjuvant chemoradiotherapy; randomized controlled trial

Mesh:

Year:  2018        PMID: 29374717     DOI: 10.21873/anticanres.12299

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Controlling lymph node micrometastases by neoadjuvant chemotherapy affects the prognosis in advanced esophageal squamous cell carcinoma.

Authors:  Yoko Hiraki; Yutaka Kimura; Motohiro Imano; Hiroaki Kato; Mitsuru Iwama; Osamu Shiraishi; Atsushi Yasuda; Masayuki Shinkai; Tomoki Makino; Masaaki Motoori; Makoto Yamasaki; Hiroshi Miyata; Takao Satou; Taroh Satoh; Hiroshi Furukawa; Masahiko Yano; Yuichiro Doki; Takushi Yasuda
Journal:  Surg Today       Date:  2020-06-28       Impact factor: 2.549

2.  Role of chemotherapy after curative esophagectomy in squamous cell carcinoma of the thoracic esophagus: A propensity score-matched analysis.

Authors:  Kai Zhu; Peng Ren; Yueyang Yang; Ying Wang; Wanyi Xiao; Hongdian Zhang; Zhentao Yu
Journal:  Thorac Cancer       Date:  2021-05-04       Impact factor: 3.500

3.  Elective nodal irradiation versus involved-field irradiation in patients with esophageal cancer receiving neoadjuvant chemoradiotherapy: a network meta-analysis.

Authors:  Tingting Liu; Silu Ding; Jun Dang; Hui Wang; Jun Chen; Guang Li
Journal:  Radiat Oncol       Date:  2019-10-16       Impact factor: 3.481

4.  Pathological complete response after neoadjuvant treatment determines survival in esophageal squamous cell carcinoma patients (NEOCRTEC5010).

Authors:  Jianfei Shen; Min Kong; Hong Yang; Ke Jin; Yuping Chen; Wentao Fang; Baofu Chen; Chengchu Zhu; Zhentao Yu; Weimin Mao; Jiaqing Xiang; Yongtao Han; Zhijian Chen; Haihua Yang; Jiaming Wang; Qingsong Pang; Xiao Zheng; Huanjun Yang; Tao Li; Xu Zhang; Qun Li; Geng Wang; Teng Mao; Xufeng Guo; Ting Lin; Mengzhong Liu; Dehua Ma; Minhua Ye; Chunguo Wang; Zheng Wang; Alessandro Brunelli; Robert J Cerfolio; Xavier Benoit D'Journo; Hiran C Fernando; Florian Lordick; Jianhua Fu
Journal:  Ann Transl Med       Date:  2021-10

5.  Lymph Node and Bone Marrow Micrometastases Define the Prognosis of Patients with pN0 Esophageal Cancer.

Authors:  Karl-F Karstens; Tarik Ghadban; Katharina Effenberger; Guido Sauter; Klaus Pantel; Jakob R Izbicki; Yogesh Vashist; Alexandra König; Matthias Reeh
Journal:  Cancers (Basel)       Date:  2020-03-04       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.